Last reviewed · How we verify

NCT05053620: ARCUATAS

Astigmatism Correction With Intrastromal Arcuate Incisions in Eyes Undergoing Cataract Surgery With Femtosecond Laser Using the Cassini Ambient With Iris Registration (ARCUATAS)

Completed Last updated 22 May 2023
What this trial tests

trial testing Calculation of the arcuate intrasomal incisions in Cataract in 22 participants. Completed in 18 April 2023.

Timeline
19 October 2021
Primary endpoint
18 April 2023
18 April 2023

Quick facts

Lead sponsorOFTALVIST (Oftalmología Vistahermosa S.L)
StatusCompleted
Study typeOBSERVATIONAL
Enrollment22
Start date19 October 2021
Primary completion18 April 2023
Estimated completion18 April 2023
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

OFTALVIST (Oftalmología Vistahermosa S.L)

Who can join

18 and older, any sex, with Cataract or Astigmatism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational, prospective follow-up post-marketing study of CE marked medical devices aimed at treating astigmatism in patients with cataracts. The main objective is to evaluate the response of the intrastromal arcuate incisions procedure for the correction of low corneal astigmatism with the Catalys femtosecond laser using the Cassini Ambient equipment with iris registration in cataract surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cataract

Currently open trials in the same condition.

Other OFTALVIST (Oftalmología Vistahermosa S.L) trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05053620.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing